Overview Dividends

(HRMY) Harmony Biosciences Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4131971040

Medication, Wakix, Narcolepsy Treatment

HRMY EPS (Earnings per Share)

EPS Growth (3Y CAGR): -23.79%
EPS Trend (3Y Correlation): -15.3%

HRMY Revenue

Revenue Growth (3Y CAGR): 21.56%
Revenue Trend (3Y Correlation): 94.6%

Description: HRMY Harmony Biosciences Holdings

Harmony Biosciences Holdings (NASDAQ:HRMY) is a US-based pharmaceutical company. The companys market capitalization stands at approximately $2.04 billion, indicating a moderate size within the industry. Its stock is classified as a common stock, providing shareholders with ownership rights.

The pharmaceutical sub-industry is characterized by high research and development costs, stringent regulatory requirements, and significant competition. Harmonys performance can be evaluated through key metrics such as Return on Equity (ROE), which is reported at 24.29%, suggesting a relatively strong ability to generate profits from shareholder equity.

The companys valuation multiples, including a Price-to-Earnings (P/E) ratio of 13.11 and a forward P/E of 9.29, indicate the markets expectations for its future earnings growth. These multiples are relatively moderate, suggesting that the stock may be reasonably valued compared to its earnings.

Key economic drivers for Harmony Biosciences include the demand for its pharmaceutical products, the success of its research and development pipeline, and the competitive landscape within the industry. The companys ability to manage its cost structure, including research and development expenses, sales and marketing costs, and general administrative expenses, will also be crucial in determining its profitability.

To further assess the companys performance, additional KPIs such as revenue growth rate, gross margin, and operating margin should be examined. These metrics will provide insights into Harmonys ability to expand its top line, maintain pricing power, and manage its operating expenses.

HRMY Stock Overview

Market Cap in USD	2,122m
Sub-Industry	Pharmaceuticals
IPO / Inception	2020-08-19

HRMY Stock Ratings

Growth Rating	-24.1%
Fundamental	87.7%
Dividend Rating	-
Return 12m vs S&P 500	-29.5%
Analyst Rating	4.33 of 5

HRMY Dividends

Currently no dividends paid

HRMY Growth Ratios

Growth Correlation 3m	58.5%
Growth Correlation 12m	-13.7%
Growth Correlation 5y	-24.5%
CAGR 5y	-9.38%
CAGR/Max DD 3y	-0.14
CAGR/Mean DD 3y	-0.21
Sharpe Ratio 12m	0.22
Alpha	-28.39
Beta	0.689
Volatility	43.40%
Current Volume	808.2k
Average Volume 20d	536.3k
Stop Loss	31 (-4.6%)
Signal	0.24

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (180.9m TTM) > 0 and > 6% of Revenue (6% = 46.4m TTM)

FCFTA 0.23 (>2.0%) and ΔFCFTA -1.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 66.17% (prev 47.52%; Δ 18.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 259.4m > Net Income 180.9m (YES >=105%, WARN >=100%)

Net Debt (-374.0m) to EBITDA (265.0m) ratio: -1.41 <= 3.0 (WARN <= 3.5)

Current Ratio 3.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (58.4m) change vs 12m ago 1.54% (target <= -2.0% for YES)

Gross Margin 78.34% (prev 77.60%; Δ 0.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 78.57% (prev 76.44%; Δ 2.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 15.04 (EBITDA TTM 265.0m / Interest Expense TTM 16.0m) >= 6 (WARN >= 3)

Altman Z'' 5.21

(A) 0.46 = (Total Current Assets 691.4m - Total Current Liabilities 180.1m) / Total Assets 1.11b

(B) 0.08 = Retained Earnings (Balance) 87.6m / Total Assets 1.11b

(D) 0.26 = Book Value of Equity 87.8m / Total Liabilities 334.9m

Total Rating: 5.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 87.70

1. Piotroski 6.50pt = 1.50

2. FCF Yield 14.96% = 5.0

3. FCF Margin 33.49% = 7.50

4. Debt/Equity 0.22 = 2.48

5. Debt/Ebitda 0.65 = 2.18

6. ROIC - WACC 13.12% = 12.50

7. RoE 26.32% = 2.19

8. Rev. Trend 94.60% = 4.73

9. Rev. CAGR 21.56% = 2.50

10. EPS Trend -15.30% = -0.38

11. EPS CAGR -23.79% = -2.50

What is the price of HRMY shares?

As of September 16, 2025, the stock is trading at USD 32.50 with a total of 808,186 shares traded.
Over the past week, the price has changed by -9.29%, over one month by -11.85%, over three months by -1.22% and over the past year by -16.15%.

Is Harmony Biosciences Holdings a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Harmony Biosciences Holdings (NASDAQ:HRMY) is currently (September 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 87.70 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HRMY is around 28.61 USD . This means that HRMY is currently overvalued and has a potential downside of -11.97%.

Is HRMY a buy, sell or hold?

Harmony Biosciences Holdings has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy HRMY.

Strong Buy: 5
Buy: 3
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HRMY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	50.6	55.5%
Analysts Target Price	50.6	55.5%
ValueRay Target Price	31.8	-2.3%

Last update: 2025-09-03 04:39

HRMY Fundamental Data Overview

Market Cap USD = 2.12b (2.12b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 565.3m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 11.9
P/E Forward = 10.3627
P/S = 2.7473
P/B = 2.7454
Beta = 0.839
Revenue TTM = 772.5m USD
EBIT TTM = 241.2m USD
EBITDA TTM = 265.0m USD
Long Term Debt = 153.3m USD (from longTermDebt, last quarter)
Short Term Debt = 18.8m USD (from shortTermDebt, last quarter)
Debt = 172.1m USD (Calculated: Short Term 18.8m + Long Term 153.3m)
Net Debt = -374.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.73b USD (2.12b + Debt 172.1m - CCE 565.3m)
Interest Coverage Ratio = 15.04 (Ebit TTM 241.2m / Interest Expense TTM 16.0m)
FCF Yield = 14.96% (FCF TTM 258.7m / Enterprise Value 1.73b)
FCF Margin = 33.49% (FCF TTM 258.7m / Revenue TTM 772.5m)
Net Margin = 23.42% (Net Income TTM 180.9m / Revenue TTM 772.5m)
Gross Margin = 78.34% ((Revenue TTM 772.5m - Cost of Revenue TTM 167.3m) / Revenue TTM)
Tobins Q-Ratio = 19.70 (Enterprise Value 1.73b / Book Value Of Equity 87.8m)
Interest Expense / Debt = 2.12% (Interest Expense 3.65m / Debt 172.1m)
Taxrate = 24.14% (46.3m / 191.8m)
NOPAT = 182.9m (EBIT 241.2m * (1 - 24.14%))
Current Ratio = 3.84 (Total Current Assets 691.4m / Total Current Liabilities 180.1m)
Debt / Equity = 0.22 (Debt 172.1m / last Quarter total Stockholder Equity 773.1m)
Debt / EBITDA = 0.65 (Net Debt -374.0m / EBITDA 265.0m)
Debt / FCF = 0.67 (Debt 172.1m / FCF TTM 258.7m)
Total Stockholder Equity = 687.4m (last 4 quarters mean)
RoA = 16.33% (Net Income 180.9m, Total Assets 1.11b )
RoE = 26.32% (Net Income TTM 180.9m / Total Stockholder Equity 687.4m)
RoCE = 28.69% (Ebit 241.2m / (Equity 687.4m + L.T.Debt 153.3m))
RoIC = 21.15% (NOPAT 182.9m / Invested Capital 864.9m)
WACC = 8.03% (E(2.12b)/V(2.29b) * Re(8.55%)) + (D(172.1m)/V(2.29b) * Rd(2.12%) * (1-Tc(0.24)))
Shares Correlation 3-Years: -54.55 | Cagr: -0.42%
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.24% ; FCFE base≈240.3m ; Y1≈252.8m ; Y5≈296.8m
Fair Price DCF = 82.26 (DCF Value 4.73b / Shares Outstanding 57.5m; 5y FCF grow 5.64% → 3.0% )
Revenue Correlation: 94.60 | Revenue CAGR: 21.56%
Rev Growth-of-Growth: -9.27
EPS Correlation: -15.30 | EPS CAGR: -23.79%
EPS Growth-of-Growth: 88.40

Additional Sources for HRMY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle